Skip to main content
  • English
  • Català
  • Español
Home
  • Company
    • Overview & History
    • Team
    • Join Oryzon
  • Epigenetics
    • Histone Code Hypothesis
    • Modulator Enzymes
    • LSD1 & Disease
    • Technology Platforms
    • Scientific Publications by Oryzon
  • Therapeutic Programs
    • Strategy
    • LSD1 & Cancer
    • Oryzon's Pipeline
  • Collaborative Research
    • Collaborative Projects
  • For Patient
    • Patient Information
  • Shareholders and Investors
    • Investor Information and News
    • Share Information
    • Events & Presentations
    • Financial Information & Downloads
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Press Releases
  • Contact
    • General Contact
    • Investor Contact
    • Email Alerts

News

Archive

  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010

News & Press Releases

15 September 2011
Oryzon will launch its first product onto the market
13 September 2011
ORYZON, PALO BIOPHARMA AND AROMICS awarded with funding for JOINT research program
7 July 2011
Oryzon on the official program of the Euromediag International Convention (EIC 2011)
6 July 2011
Dr. Marta Palicio, Scientific Business Developer at Oryzon, has been invited to participate in the roundtable Biomarkers and translational medicine: new paradigms for personalized medicine
27 June 2011
Oryzon is present at the Bio International Convention of USA
8 June 2011
Oryzon is present in the 76th Spanish National Congress of Urology
17 May 2011
Oryzon presents the results of the clinical study of GynEC-Dx: detection of endometrial cancer product
1 March 2011
Oryzon to Present Recent Advances from its Project 'Innovative Approaches and Biomarkers in Parkinson Disease' at a Symposium in Barcelona
12 November 2010
Oryzon Licenses Human Antibody Phage Display Technology for Discovery of Novel Therapeutics

Pages

  • « first
  • ‹ previous
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15

epigen-logo

Epigenetic drugs for a better world.

United States

Oryzon Corporate
245 First Street, Suite 1800
Cambridge, MA 02142

T: (617) 444-8786
F: (617) 444- 8405
info@oryzon.com

Spain

Oryzon Genomics
Sant Ferran 74
08940 Cornellà de Llobregat, Barcelona, Spain

T: (+34) 93 515 1313
F: (+34) 93 377 4028
info@oryzon.com

Legal Advice
Privacy Policy

Investor Information

ISIN: ES0167733015 - ORY

Please contact us for investor information.

Contact Us

© 2019

Oryzon Genomics

All Rights Reserved

  • Legal Advice
  • Privacy Policy
  • Registered address: Carrera de San Jerónimo 15, 2ª planta, 28014 Madrid (Spain)